South Korea
· Delayed Price · Currency is KRW Keeps Biopharma Statistics
Total Valuation
Keeps Biopharma has a market cap or net worth of KRW 392.97 billion. The enterprise value is 446.29 billion.
| Market Cap | 392.97B |
| Enterprise Value | 446.29B |
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Keeps Biopharma has 19.08 million shares outstanding. The number of shares has decreased by -0.20% in one year.
| Current Share Class | 19.08M |
| Shares Outstanding | 19.08M |
| Shares Change (YoY) | -0.20% |
| Shares Change (QoQ) | -2.23% |
| Owned by Insiders (%) | 4.34% |
| Owned by Institutions (%) | 0.86% |
| Float | 14.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.88 |
| PB Ratio | 5.61 |
| P/TBV Ratio | 39.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 109.29, with an EV/FCF ratio of -43.85.
| EV / Earnings | -61.24 |
| EV / Sales | 3.27 |
| EV / EBITDA | 109.29 |
| EV / EBIT | n/a |
| EV / FCF | -43.85 |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 0.89.
| Current Ratio | 0.98 |
| Quick Ratio | 0.51 |
| Debt / Equity | 0.89 |
| Debt / EBITDA | 11.19 |
| Debt / FCF | -6.15 |
| Interest Coverage | 0.63 |
Financial Efficiency
Return on equity (ROE) is -4.22% and return on invested capital (ROIC) is 1.48%.
| Return on Equity (ROE) | -4.22% |
| Return on Assets (ROA) | 1.17% |
| Return on Invested Capital (ROIC) | 1.48% |
| Return on Capital Employed (ROCE) | 2.96% |
| Revenue Per Employee | 4.88B |
| Profits Per Employee | -260.29M |
| Employee Count | 28 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 7.89 |
Taxes
In the past 12 months, Keeps Biopharma has paid 1.76 billion in taxes.
| Income Tax | 1.76B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +210.96% in the last 52 weeks. The beta is 1.67, so Keeps Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.67 |
| 52-Week Price Change | +210.96% |
| 50-Day Moving Average | 14,833.20 |
| 200-Day Moving Average | 8,715.40 |
| Relative Strength Index (RSI) | 54.87 |
| Average Volume (20 Days) | 717,273 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Keeps Biopharma had revenue of KRW 136.52 billion and -7.29 billion in losses. Loss per share was -388.54.
| Revenue | 136.52B |
| Gross Profit | 20.20B |
| Operating Income | 2.88B |
| Pretax Income | -1.07B |
| Net Income | -7.29B |
| EBITDA | 5.59B |
| EBIT | 2.88B |
| Loss Per Share | -388.54 |
Balance Sheet
The company has 24.08 billion in cash and 62.59 billion in debt, giving a net cash position of -38.51 billion or -2,018.64 per share.
| Cash & Cash Equivalents | 24.08B |
| Total Debt | 62.59B |
| Net Cash | -38.51B |
| Net Cash Per Share | -2,018.64 |
| Equity (Book Value) | 70.06B |
| Book Value Per Share | 2,896.41 |
| Working Capital | -1.34B |
Cash Flow
In the last 12 months, operating cash flow was -3.16 billion and capital expenditures -7.02 billion, giving a free cash flow of -10.18 billion.
| Operating Cash Flow | -3.16B |
| Capital Expenditures | -7.02B |
| Free Cash Flow | -10.18B |
| FCF Per Share | -533.49 |
Margins
Gross margin is 14.80%, with operating and profit margins of 2.11% and -5.34%.
| Gross Margin | 14.80% |
| Operating Margin | 2.11% |
| Pretax Margin | -0.78% |
| Profit Margin | -5.34% |
| EBITDA Margin | 4.10% |
| EBIT Margin | 2.11% |
| FCF Margin | n/a |
Dividends & Yields
Keeps Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.20% |
| Shareholder Yield | 0.20% |
| Earnings Yield | -1.85% |
| FCF Yield | -2.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 20, 2020. It was a forward split with a ratio of 3.
| Last Split Date | May 20, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Keeps Biopharma has an Altman Z-Score of 1.48 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.48 |
| Piotroski F-Score | 2 |